Patent ID: 6458836
Filing Date: 2002-10-01
Classification: A61K,Y10S

Abstract:
A process for the long term treatment or prophylactic management of ocular hypertension or glaucoma in a human patient by topical ocular administration of a therapeutically effective amount of a prostaglandin related compound at least once a day for at least six months, the improvement to eliminate or reduce potential pigmentation of the iris of a treated eye occurring by said long-term topical ocular application of a prostaglandin related compound, wherein the compound used has the formula (I) wherein W1, W2, and W3 are carbon or oxygen atoms, L, M and N are hydrogen atom, hydroxy, halogen atom, lower alkyl, lower alkoxy, hydroxy (lower)alkyl, or oxo, wherein at least one of L and M is a group other than hydrogen, and the five-membered ring may have at least one double bond; A is â€”CH2OH, â€”COCH2OH, â€”COOH or a functional derivative thereof; B is single bond, â€”CH2â€”, â€”CH2â€”CH2â€”, â€”CH&boxH;CHâ€”, â€”Câ‰¡Câ€”, â€”CH2â€”CH2â€”CH2, â€”CH&boxH;CHâ€”CH2, â€”CH2â€”CH&boxH;CHâ€”, â€”CHâ‰¡Câ€”Ch2â€”, or â€”CH2â€”Câ‰¡Câ€”; R1 is a saturated or unsaturated bivalent lower or medium aliphatic hydrocarbon residue, which is unsubstituted or substituted with halogen, an alkyl group, hydroxy, oxo, aryl or heterocyclic group; and Ra is a saturated or unsaturated lower or medium aliphatic hydrocarbon residue, which is unsubstituted or substituted with halogen atom, oxo, hydroxy, lower alkyl, lower alkoxy, lower alkanoyloxy, cyclo(lower)alkyl, cyclo(lower)alkyloxy, aryl, aryloxy, heterodcyclic group or heterocyclic-oxy group; cyclo(lower)alkyl; cyclo(lower)alkyloxy; aryl; aryloxy; heterocyclic group; or hetrocyclic-oxy group.